SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Mikko S)
 

Search: WFRF:(Mikko S) > Avidity-Based Affin...

  • Akkilic, NamikAstraZeneca AB (author)

Avidity-Based Affinity Enhancement Using Nanoliposome-Amplified SPR Sensing Enables Low Picomolar Detection of Biologically Active Neuregulin 1

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • 2019-11-14
  • American Chemical Society (ACS),2019

Numbers

  • LIBRIS-ID:oai:research.chalmers.se:6ff6cf34-0b06-4749-af36-b370c32f1690
  • https://doi.org/10.1021/acssensors.9b01392DOI
  • https://research.chalmers.se/publication/515077URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Biomarkers serve as indicators of disease progression or therapeutic response of an medical intervention, and means for enabling a reliable and sensitive biomarker detection are therefore vital in clinical settings. Most biosensor assays require high-affinity interactions in combination with an enzyme or fluorescent tag to enable detection and frequently employ extensive washing procedures prior to signal readout. Attempts to overcome this limitation by using natural biological partners tend to be demanding, because their very low affinity is frequently not compatible with the need of reaching low limits of detection (LODs), especially for circulating biomarkers that possess short half-lives. To address these challenges, we developed a label-free surface plasmon resonance (SPR) platform for the detection of neuregulin 1 (NRG1) using ErbB4-modified liposomes offering both signal amplification and affinity enhancement via functional multivalent interactions. Through the functional avidity interaction between NRG1 and ErbB4, an LOD of 3.5 picomolar was reached, which is about 60-fold higher than traditional SPR and miniaturized immunoassays. The biosensor displays also an 8-fold higher sensitivity when compared with a single-molecule immunoassay employing the natural binding partner rather than a high-affinity antibody as one of the interaction partners. In fact, the liposome-induced avidity between NRG1 and ErbB4 offered an LOD that was comparable to that obtained using a high-affinity antibody and enabled detection of NRG1 in plasma with a LOD of 36 pM. Employing the liposome-enhanced platform in conjunction with a low-affinity biomarker receptor thus enables the assessment of the functional state of the biomarker at competitive LODs and eliminates the need for high-affinity antibodies.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Liljeblad, MathiasAstraZeneca AB (author)
  • Blaho, StefanAstraZeneca AB (author)
  • Hölttä, MikkoAstraZeneca AB (author)
  • Höök, Fredrik,1966Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)fredrikh (author)
  • Geschwindner, S.AstraZeneca AB (author)
  • AstraZeneca ABChalmers tekniska högskola (creator_code:org_t)

Related titles

  • In:ACS Sensors: American Chemical Society (ACS)4:12, s. 3166-31742379-3694

Internet link

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view